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ABSTRACT 
Today, the vast majority of drugs available for patient use have 
gone through a rigorous system of human clinical trials supervised by 
the Food and Drug Administration (FDA), to ensure the drugs are safe 
and efficacious. There are now citizen advocacy groups that seek use of 
drugs not yet approved by the FDA, to be administered to terminally ill 
patients who have exhausted all other available means of therapy. The 
FDA has programs for terminal patients, under the supervision of their 
physicians, to use unapproved drugs; however, the advocacy groups seek 
access to drugs in much earlier phases than is now allowed, raising 
serious safety concerns for patients. Use of drugs outside of the clinical 
trials system undermines the integrity of the FDA’s drug development 
process by slowing enrollment, which in turn slows approval and timely 
access of safe and efficacious drugs to all of society.  
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Introduction 
The U.S. Food and Drug Administration (FDA) walks a fine line 
between ensuring drug safety and approving effective therapies in a 
timely manner. The agency comes under fire both for moving too 
slowly in approving drugs and for allowing access to potentially 
dangerous substances. The pivotal question is, How are patients best 
served? Is it better to have a drug approval system that facilitates 
access to promising drugs, even if it means sacrificing opportunities 
to collect more rigorous information that could guide clinical 
decision-making down the road? Or is it better to enact measures 
that restrict access to experimental drugs in order to preserve the 
ability of the clinical trial process to develop rigorous, long-term 
medical information? The aim of this paper is to review the history 
and current status of the FDA drug-approval process and to examine 
problems with and ways to improve the process, with specific 
emphasis on new cancer treatments.  
The FDA drug approval system has many deficiencies. The 
current system has served well for the last 50 years, but the 
demands of 21st century medicine are beginning to disclose 
problems, through dwindling approvals of new drugs, incremental 
improvements in cancer treatments, and patient dissatisfaction. 
Patient advocacy groups, such as the Abigail Alliance, and some U.S. 
senators have sued the FDA in court and introduced bills in Congress 
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that would allow the use of experimental drugs not yet approved by 
the FDA for marketing or compassionate use (Harris, 2007). Now 
more than ever, the clinical trials process needs to be strengthened 
with new innovations and increased enrollment. Because of the 
potential effect on the safety of patients, and the integrity and value 
of the FDA clinical trial system of making drugs safe for society as a 
whole, non-approved experimental drugs should not be available for 
use outside the FDA clinical trial system. 
  
History of the FDA 
The FDA is a regulatory, scientific, and public health agency 
that oversees most food products, human and animal drugs, 
biological therapeutic agents, medical devices, cosmetics, animal 
feeds, and radiation-emitting products for consumer use (Kurian, 
1998). The agency also advances public health by accelerating 
innovations that make medicines safer, more effective, and more 
affordable, while supplying accurate science-based information the 
public needs to use these medications effectively (U.S. Food and 
Drug Administration, 2006). 
 The modern clinical trial process was founded in 1938, in the wake 
of a therapeutic disaster (Kurian, 1998). In 1937, a drug company 
combined sulfanilamide with diethylene glycol, a highly toxic form of 
antifreeze. The drug was used to treat streptococcal infections. This 
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concoction killed more than 100 persons. Congress reacted swiftly by 
passing a bill called the Food Drug and Cosmetic Act (FD&C Act) of 1938 
(Milestones in U.S.FDA Food and Drug Law History, 1999). This act 
states that no person “shall introduce or deliver for introduction into 
interstate commerce any new drug unless” (Milestones in U.S.FDA Food 
and Drug Law History 1999) an approval of a New Drug Application 
(NDA) or Abbreviated New Drug Application (ANDA) is effective with 
respect to that drug (History of the FDA, 2006). An NDA is the vehicle by 
which drug sponsors formally propose that the FDA approve a new 
pharmaceutical for sale and marketing in the U.S. The data gathered 
during animal studies and human clinical trials of an Investigational 
New Drug become part of the NDA. Through these trials, the sponsor 
must provide substantial evidence that the drug will have the effect it is 
represented to have (History of the FDA, 2006). An AND, a shortened 
version, may be submitted instead of an NDA for approval of a new 
formulation of an existing drug or investigational drugs that are similar 
to already approved drugs (Title 21 Code of Federal Regulations 314.93, 
n.d.). 
The Kefauver-Harris Amendment to the FD&C Act was passed in 
1962 as a result of thousands of birth defects in Western Europe, due to 
the use of thalidomide (Drugs and Food Under the 1938 ACT and Its 
Amendments, n.d.). The FDA succeeded in keeping the drug off the U.S. 
markets and received a lot of positive press. From this point onward, the 
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FDA demanded both efficacy and safety before granting final approval to 
market a drug. In 1997, Congress enacted section 561 of the FDCA, 
which permitted additional exemptions, on a compassionate basis, for 
treatment with investigational drugs outside the confines of an FDA-
regulated clinical trial. 
 
The Abigail Alliance 
If you ask a random group of people in the street whether a 
terminal patient, soon to die, should be allowed access to 
unapproved drugs before they are proven safe and efficacious, an 
overwhelming majority will probably say yes. In October 2005, the 
Abigail Alliance for Better Access to Development of Drugs, a 
citizens’ group of terminally ill patients and their supporters, sued 
the FDA, seeking to challenge the regulatory policies for 
investigational drugs. The Abigail Alliance wanted patients whose 
physician had determined that their condition was terminal to 
have access to drugs that had passed Phase I of testing and that 
were now considered safe enough to move to Phase II (Okie, 2006). 
The case was heard before a three-judge panel of the U.S. Court of 
Appeals in Washington, DC. The Alliance attempted to establish an 
implied fundamental right that they said had already been secured 
by the Constitution, basing their claim on the guarantee to life and 
liberty in the Due Process Clause of the Fifth Amendment (Okie). 
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The Alliance asserted that, if terminal patients have an implied 
fundamental right to refuse treatment and die, a right that had 
already been granted by the U.S. Supreme Court (Cruzan v. 
Director, Missouri Department of Health, 1990), then that right 
should guarantee the choice to live and to pursue access to 
investigational drugs, if that is the only remaining alternative. The 
Alliance questioned whether Congress and the FDA had struck the 
right balance between early access and safety for the terminally ill 
(Kaufman, 2006).  
The Abigail Alliance’s lawsuit suggested to the FDA that 
there should be a “different risk-benefit trade off” for terminally ill 
patients with no other treatment options, as opposed to patients 
with treatment options. The efforts of the Alliance succeeded 
(Emmanuel, 2006), and in May 2006 they won their case by a  
two-to-one decision, ensuring dying patients the constitutional 
right to use any drug that had passed the first clinical test phase, 
as long as the pharmaceutical company agreed to make and sell or 
donate it. The drawback of the decision was that the drug company 
could not be forced to sell their drug, and in many cases, there 
would not be enough of a drug manufactured to distribute it 
outside of the clinical trials. The Alliance said their patients would 
purchase a drug if the sponsor was not willing to donate it (“Citizen 
Petition of the Abigail Alliance and the Washington Legal 
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Foundation,” 2006). The minority opinion, given by Judge Griffith, 
then questioned, “If a terminally ill patient has such a right, are 
patients with seriously ill conditions entitled to benefit from the 
same logic? If an indigent cannot afford potentially lifesaving 
drugs, then where is the justice?’ (Alliance for Better Access to 
Developmental Drugs v Von Eschenbach, 2006, p. 486).  
The track record for drugs in very early phase trials has not 
been very encouraging. Of all the cancer drugs that enter clinical 
testing, only 5% are ever approved for patient use, and of the 
cancer drugs that move to Phase II, only 30% proceed to Phase III 
(Kola, 2004). Therefore, the odds that a drug in this early stage of 
testing will be safe and efficacious are slim, causing concern for 
the FDA about serious adverse events that might occur outside of a 
trial, further eroding the public’s faith in the drug approval 
process. Administration of these drugs by physicians who have 
little familiarity with the drug as far as dosage and the potential for 
side effects would create additional safety issues. Use of 
unapproved drugs would also be problematic for physicians, whose 
desire to help their patients conflicts with their ethical obligation to 
do no harm. Furthermore, there is the possibility of a malpractice 
suit, when serious adverse events or deaths occur. How would one 
differentiate between death caused by the experimental drug and 
death due to the natural progression of disease?  
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Most pharmaceutical companies have little incentive to sell 
unapproved drugs. Their concern focuses on the fact that adverse 
events could later be used to argue against FDA approval, halting 
manufacturing and denying use of the drug to future patients. 
Under FDA regulations, furthermore, patients cannot waive 
liability for negligence, leaving them the opportunity to sue 
doctors, drug companies, and the FDA (Howley, 2007). This is 
tremendous disincentive for all involved to sell or give away 
investigational drugs outside of a clinical trial.  
As expected, the FDA was unhappy with outcome of the 
Abigail Alliance’s lawsuit, and counter-sued. Federal officials filed 
an appeal, seeking to have the case reheard. Fifteen months later, 
on August 10, 2007, the full court, which had not been present for 
the first ruling, voted 8 to 2 that terminally ill patients who have 
exhausted all treatment do not have the constitutional right to use 
experimental drugs (Cannon, 2007). 
  
Congressional Support for Access to Unapproved Drugs 
 Sam Brownback, a U.S. senator, agreed with the Abigail 
Alliance and introduced his own legislative proposal into the U.S. 
Senate in November 2005 (“Access, Compassion, Care, and Ethics 
for Seriously Ill Patients Act, 2005). His intention was to make the 
regulatory policy work for dying patients. The purpose of the 
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Access, Compassion, Care and Ethics for Seriously Ill Patients Bill 
was to obtain tier 1 approval on the basis of Phase I testing and 
preclinical evidence from case histories, animal testing, 
pharmacologic studies or computer models that the drug may be 
effective against a life-threatening illness. Unlike the Abigail 
Alliance lawsuit, however, the patient waived the right to sue the 
drug sponsor (Okie, 2006, p. 439). This bill languished in the 
Senate and never became law. However, the quest continues with a 
second bill that was introduced by Congressman Christopher 
Shays, on September 29, 2006 (Access, Compassion, Care, and 
Ethics for Seriously Ill Patients Act, 2006). Shays’ bill is an exact 
duplicate of Senator Brownback’s and was introduced in the House 
of Representatives. There has been no ruling to date.  
 
Findings of Court Cases and Congressional Hearings Related to 
Public Access to Unapproved Drugs 
The following is a summary of the findings of the Abigail 
Alliance court case and appeal, and congressional hearings 
concerning the Access, Compassion, Care and Ethics for Seriously 
Ill Patients Bill and related bills. Rebuttals to the findings are also 
summarized. 
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Finding. Placebo-controlled studies are unethical for dying 
patients. (Access, Compassion, Care, and Ethics for Seriously Ill 
Patients Act, 2006).  
Because cancer is a life-threatening illness, it is rarely 
ethical to give a placebo when something better than a placebo is 
available. Patients have to give informed consent to be in a trial, so 
they would know if the trial were using a placebo. In cancer trials, 
therefore, a new drug is tested along with a comparator or 
concoction of drugs approved for treatment of the disease. Given a 
choice, most patients diagnosed with cancer prefer the most 
recently discovered treatments (Lafferty, Bellas, & Corqage, 2004). 
A study of about 3000 active cancer trials in the National Institutes 
of Health Database showed that comparators, not placebos, were 
administered (Soares et al., 2005). 
  
Finding. The current FDA drug approval process denies the 
benefits of medical progress to seriously ill patients who face 
morbidity or death, and there are unjustified delays and denials of 
approvals of promising therapies intended to treat serious life-
threatening conditions (109th Congress, Second Session, 2006). 
The FDA has many programs that expedite experimental 
drugs to seriously ill patients, usually during Phase II or later, 
rather than immediately following Phase I. The “compassionate 
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use” program allows physicians and their patients access to 
unapproved drugs outside of an FDA-approved clinical trial. 
Navigation of this program can be somewhat frustrating. However, 
in December 2006, the FDA leadership acknowledged these 
frustrations and proposed changes that will bring additional clarity 
to the process (Gottleib, 2007). The changes clarify opportunities 
for the public to obtain drugs through compassionate/expanded 
use and other FDA programs, thus making treatment more widely 
available (Bristol, 2007). Allowing unfettered access to any therapy 
available was not considered a reasonable option.  
 The FDA grants either regular or accelerated marketing 
approval for oncology drugs (Johnson, Williams, & Pazdur, 2003). 
It is commonly believed that the FDA requires improvement in 
survival rate in order to approve a marketing application for a new 
oncology drug. However, most cancer drugs can now be approved 
based on surrogate endpoints, which shortens trials, since the 
sponsor does not have to show the drug is life saving (Schein, 
2001). A surrogate endpoint consists of either halted tumor 
progression or shrinkage of tumor size. However, such a tumor 
response does not necessarily represent a cure or life-extension 
(Fleming & DeMets, 1996).  
Regular marketing approval by the FDA does require 
substantial evidence of efficacy from adequate and well-controlled 
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clinical investigations. The attributes of these trials are explained 
in the FDA regulations (Title 21 Code of Federal Regulations, Part 
314.126). Efficacy should be demonstrated by prolongation of life. 
Subpart H, which was added to the new drug application (NDA) 
regulations in 1992, allows accelerated approval (AA) for diseases 
that are serious and life-threatening, if the drug appears to show 
benefits over existing therapies. After FDA approval of the drug 
through AA, the sponsor must continue trials to demonstrate that 
treatment with the drug is indeed associated with clinical benefit. 
If this post-marketing study fails to show clinical benefit, then the 
drug will be taken off of the market (Title 21 Code of Federal 
Regulations, Part 314.126, n.d.). Twenty-six new cancer drugs for 
treatment of thirty different clinical indications received 
accelerated approval between 1995 and 2005 (Miller, 2007).  
Single patient Investigational New Drug Applications may be 
used when the agent is available from the manufacturer, but there 
are no ongoing trials for the patient’s particular cancer. If the 
patient’s oncologist determines that there are no alternative 
medicines, the doctor can submit a request to the FDA for a Single 
Patient IND. The physician can now treat his or her patient with an 
unapproved drug (Cancer Liaison Program, n.d.).  
Another exception is available under a Special Protocol 
Exception (“Subpart B: Investigational New Drug Application,” 
 
 12 
n.d.). The patient is treated under the Sponsor’s IND Application, 
with the patient’s physician acting as an investigator. A patient 
who does not qualify for a trial because he or she does not have the 
type of cancer studied may have access to that drug outside of the 
trial. The patient’s physician is responsible for all treatment and 
must provide follow-up information to the sponsor (IND applicant). 
The FDA rarely refuses an IND application if the requested protocol 
is reasonable and all other treatment options have been exhausted. 
The rate-limiting factor in this program is usually the urgency with 
which the patient’s oncologist communicates with the FDA 
(Schwartz, 2007). 
  
Finding. The Food and Drug Administration Advisory 
Committee should have greater representation of medical clinicians 
and laypersons to represent interests of seriously ill patients. 
The FDA Oncologic Drugs Advisory Committee consists of 
nine oncologists, two oncology nurses, and one person with a 
Ph.D. in statistics (FDA U.S. Food and Drug Administration, 
2007a). There is also an Advisory Committee of Consumer 
Representatives (U.S. Food and Drug Administration, 2007b). 
Consumer representatives play an important role in committee 
deliberations. This committee consists of representatives from 
interested consumers, consumer organizations, coalitions, and 
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associations that help to facilitate dialogue on scientific issues that 
affect all drug consumers. In addition, any individual can 
communicate with the FDA by commenting on new and revised 
FDA regulations through the Federal Register or through electronic 
dockets on their Web site, as well as by attending public meetings.  
The FDA also has a Patient Representatives Program that is 
responsible for presenting the FDA with the individual and unique 
perspective of the patient and his/her family members (U.S. Food 
and Drug Administration, 2007c). The patient representative 
advises the FDA when products and therapies are presented for 
the diagnosis and treatment of cancer and HIV/AIDS. Patient 
representatives may also advise the FDA on products and 
therapies that relate to other serious and life-threatening diseases, 
on a case-by-case basis. The Office of Special Health Issues (OSHI), 
along with other FDA staff, assists the patient representative. The 
patient representative may serve as a voting or nonvoting member 
of an advisory committee and can be nominated by himself or by 
someone else (U.S. Food and Drug Administration, 2007c). The 
Patient Representatives Program could provide a means for 
members of the Abigail Alliance and other patient advocacy groups 
to have a voice in the FDA drug approval process and in gaining 
patient access to unapproved drugs. 
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Finding. The use of available investigational drugs for 
treatment is the responsibility of the physician and patient. 
 It is true that a patient’s oncologist should have firsthand 
knowledge of the patient’s disease and current situation. However, 
physicians of non-trial patients are not familiar with the dosing, 
metabolism, and possible adverse effects of an unapproved drug. 
By Phase II, the stage at which the Abigail Alliance wishes drugs to 
be made accessible to the public, only a handful of humans have 
been exposed to the experimental drug. The majority of adverse 
events do not usually show up until thousands of patients have 
used a drug for many months. This is the main reason for post-
marketing surveillance (Strom, 2006). 
 
Objections to the Abigail Alliance and Congressional Bills Supporting 
Public Access to Unapproved Drugs 
  In 2006, The National Coalition for Cancer Survivorship 
(NCCS), the American Society of Clinical Oncology (ASCO), and the 
Association of American Medical Colleges (AAMC) submitted an 
amicus (friend of the Court) brief to the Washington, D.C., Circuit 
Court of Appeals in support of the FDA (American Society of 
Clinical Oncology, 2007). Collectively, these groups stated that 
investigational drugs should not be commercially available, 
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because Phase I trials do not provide an adequate assessment of 
safety, let alone efficacy.  
The Society for Clinical Trials, an organization committed to 
the development of reliable study designs for experimental drugs, 
voiced concern about the proposed legislation and its potential for 
substantial adverse events on public health (Society for Clinical 
Trials Board of Directors, 2006). Every drug that reaches Phase I 
testing looks promising; otherwise it would not be moving to Phase 
II. In reality, there are only a handful of breakthrough drugs 
among the hundreds under development at any given time (Begg, 
Brawley, Califf, & DeMets, 2006). Even if a cancer drug passes 
Phase I testing, only one in ten is approved for marketing (Parexel 
Corporation, 2005). The Society for Clinical Trials totally disagreed 
with the Abigail Alliance’s criticism of the FDA’s rigorous scientific 
method for drug approval, which is based on decades of experience 
(Begg et al., p. 155). This approach to drug testing is widely 
accepted by the scientific community, because the data obtained 
from randomized controlled trials provide conclusive and reliable 
data.  
 
A New Drug Is Not Always a Better Drug 
  Given a choice, most patients diagnosed with cancer would 
probably seek out the newest treatment available to them, even if it 
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involved a relatively untried medication. In our culture, “new” 
usually implies better or improved. Yet, in medicine, this does not 
always turn out to be true. In drug development, therapeutic 
benefits are proven in randomized controlled trials (RCTs). As the 
practice of medicine becomes increasingly scientific and less 
accepting of unsupported opinion, the RCT has become the 
standard technique for changing diagnostic or therapeutic 
methods. Dr. Anthony Fauci, director of the National Institute of 
Allergy and Infectious Disease, stated that the goal of a RCT is “not 
to deliver therapy, it is to answer a scientific question, so that the 
drug can be available for everybody, once you have determined 
safety and efficacy” (Hellman & Hellman, 1999, p.1586).  
In some cases, therapy regimens have turned out to be 
disastrous, especially those that have not been proven safe and 
efficacious by a previous RCT. This was the case with one of the 
highest profile treatments to be widely used outside the research 
setting before there was solid evidence that it was beneficial 
(Appelbaum, 1996). The treatment was high-dose chemotherapy 
combined with autologous bone marrow transplantation (HDC + 
ABMT), which was administered to patients with solid-tumor 
cancers, such as lung, breast, and ovarian cancer (Cheson, Lacerna, 
Leyland-Jones, & Sarosy 1989). Researchers thought that giving 
very high doses of chemotherapy would be the patients’ best hope. 
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After the chemotherapy, the transplant would return the bone 
marrow to normal. Data from very early studies led some 
researchers to conclude the new treatment was better than the 
standard treatment. A spokesperson for the National Cancer 
Institute (NCI; 2007) said that the preliminary evidence was very 
convincing, and those words spread through newspapers, such as 
the New York Times, like wildfire. Encouraged by this news, patients 
begged their doctors to prescribe and demanded that their insurance 
companies pay for the very expensive treatment. So many women 
received the therapy outside of the clinical trial process that it took 
years for investigators to enroll enough women to fill their RCT in 
order to determine which regimen really was superior (Welch, 2002). 
When, in 2000, results of the RCT began to trickle in, the results 
were sobering. Women who received the standard therapy did just 
as well as those that received the new HDC + ABMT therapy, with 
fewer complications and deaths (“High-Dose Chemotherapy,” 2000). 
Many of the complications were due to the high doses of 
chemotherapy and infections from bone marrow deficiencies, not 
from their cancers. For more than 10 years, desperately ill patients 
sought bone marrow transplantation as their last hope. Millions of 
health-care dollars and resources were wasted on an unapproved 
therapy regimen (Eddy, 1992). The New York Times published the 
sad truth: “As a society, we have to accept that rigorous evaluation 
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of new treatment is essential. Skipping this step may seem like a 
compassionate act, but it can have devastating consequences” (Eddy 
& Henderson, 1999, p. A17).  
The case of HDC + ABMT demonstrates the problems that 
can arise and the suffering caused when drugs are used before 
they have been proven to be safe and efficacious through an FDA 
approved RCT. It also illustrates the difficulty of enrolling enough 
patients in trials to prove efficacy. There have been enormous 
strides in successful treatment of children with cancer, as a direct 
result of their high rates of participation in clinical trials. More that 
60% of pediatric cancer patients take part in trials, while adult 
enrollment is only around 3% (National “Cancer Institute Cancer 
Clinical Trials: The In-Depth Program,” 2006). Increased 
enrollment of adults in clinical trials could greatly enhance the rate 
of cancer cures. 
 
The FDA’s Critical Path Initiative 
The FDA heard the pounding on their front door loudly and 
clearly, and knew that the drug development and approval process 
was in need of a serious overhaul. In March 2004, the FDA’s 
Critical Path Initiative was introduced, with the aim of organizing 
seventy-six science and regulatory areas to improve drug 
development (FDA, 2004). The stated goal was to enhance the 
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health and well-being of “all Americans.” The agency is using its 
unique position as a drug regulatory agency to work with other 
federal agencies, stakeholders, industry, patient groups, and 
academic researchers to identify scientific hurdles that are 
impairing the efficiency of evaluating and developing FDA-
regulated products, with particular attention given to genetics-
related drugs and new diagnostic tools.  
The Critical Path Initiative is continually evolving. The FDA 
has undertaken efforts to reduce the time spent in early drug 
development, thus enabling new medical discoveries and promising 
drugs to move from the laboratory to the consumer more 
efficiently, while maintaining protection of human subjects (“FDA’s 
Critical Path Initiative Science Enhancing the Health and Well-
Being of All Americans,” 2004). The agency aims to realize more 
and faster public health benefits through the modernization of 
computer models, in vitro tests, qualified biomarkers, and 
innovative study designs, which will move the FDA drug 
development and evaluation process into the 21st century (von 
Eschenbach, 2007). 
  
Clinical Trials of New Drugs 
Today, the vast majority of patients in the United States with 
life-threatening diseases are treated with drugs that have passed 
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the FDA’s stringent evaluation process, designed to ensure that the 
drugs are safe and effective. Drug trials conducted in the U.S. are 
the most rigorous in the world. The two main drug characteristics 
examined during a clinical trial are safety and efficacy. The five 
main points investigated are (a) do the benefits of the drug 
outweigh the risks; (b) once the trial has begun, should it be 
continued, based on reports of side effects and effectiveness of the 
treatment; (c) at the completion of the trial, should the drug be 
sold to the public; (d) what claims can the manufacturer make; 
and (e) what should the labels say, as far as directions for use, side 
effects, and warnings (von Eschenbach, 2007). Although efforts are 
made to reduce risks to participants in clinical trials, some risk is 
unavoidable due to the uncertainty inherent in clinical research 
involving new medical products. Each phase of a trial has a 
specific purpose, and the potential for benefits, risks, and harm, 
may vary among different phases.  
Historically, the implementation, design, and analysis of 
clinical trials have followed well-established guidelines and 
statistical principles to accurately and objectively determine 
differences between experimental and control groups. However, the 
FDA is aware of the need for new strategies in the battle against 
cancer. Cancer is caused by specific changes or mutations in one 
or more of twenty to twenty-five thousand genes, especially genes 
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that produce substances that influence cell division (Nathan, 
2007). The significant genetic and metabolic differences among 
individual cancers need to be considered in designing trials and 
appropriate drug regimens. Genetic differences among individual 
patients may increase or decrease the risk of disease and affect 
their response to treatments. A complex and heterogeneous 
disease, cancer requires targeted therapies that demonstrate 
consistent anti-tumor response early in efficacy trials. Cancer 
trials are slowly progressing from the use of cytotoxic, or cell-
killing, drugs that not only kill cancer cells but also destroy many 
healthy cells, to smart drugs that target specific tumor types and 
block molecular pathways. Early Phase I studies using tools that 
profile gene-expression–gene-sequencing, proteomics, and 
molecular imaging can identify subgroups of patients who are 
likely to respond to a new drug or therapy (Roberts, 2004). Thus, 
patients in earlier trial phases will see more improvements in their 
cancers.  
Cancer patients who use experimental drugs outside of a 
clinical trial, on the basis that it worked for other patients with the 
same type of cancer, face high odds that the drug will not work for 
them because of genetic differences in their cancers (“Price Water 
House Coopers, 2005). Genetic differences may also render certain 
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patients more susceptible to serious adverse effects of an 
experimental drug.  
 
Phase Zero Cancer Trials 
In January 2006, the FDA announced new rules that would allow 
small doses of experimental drugs to be tested on people before full-scale 
clinical trials. Such phase zero trials are designed to evaluate the 
pharmacodynamic (PD) effects of candidate drugs at the molecular level 
in the clinic. The trials will use biopsies of target tissues to determine the 
quantitative effect of the drug after a minimum number of doses. This 
method will require repeated tumor biopsies, as well as some knowledge 
of the dose level likely to cause a tumor response (Kinders, 2007). 
Phase zero studies do not examine safety or effectiveness; instead, 
they gather data on the targeting action and metabolism of the drug in 
the body. These trials are designed to be short and use a very small 
number of human subjects, who are given very low doses of the drug. 
Phase zero trials will allow drug manufacturers to identify failing drugs 
early in the testing process and will generate data that can be used to 
design smarter Phase I trials for promising drugs. Phase zero trials are 
an improvement over the use of animal data alone as the basis for 
selecting drugs for Phase I trials. Woodcock (n.d.), the FDA's Deputy 
Commissioner for Operations, views phase zero trials as a way to protect 
patients by decreasing human exposure to compounds that ultimately 
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fail, which at this point includes the majority of experimental cancer 
drugs. 
 
Adaptive Drug Trials  
Adaptive drug trials are an example of the FDA using better 
technology and better science to speed cancer drugs through the trial 
process. In a regular phase trial of a new cancer drug, the drug is 
administered to a group of patients with various types of the disease, 
with the hope that a percentage of them will benefit. In contrast, an 
adaptive trial begins with a heterogeneous group of patients and then 
adds patients with a particular type of disease, as data from outside the 
trial suggest that these specific patients are most likely to benefit 
(Groopman, 2006). Instead of waiting until the end of the trial, the data 
are analyzed after partial enrollment. New patients are added to the 
subgroup of patients that shows the best response rate. For example, if 
the response rate is twice as high in one subgroup, then twice as many 
patients will be enrolled in that subgroup. Thus, patients benefit from 
the knowledge gained during the trial, instead of having to wait for 
completion of the trial (Galloway, 2005). Scott Gottlieb (2006), an FDA 
Deputy Commissioner, has stated that the FDA will receive criticism for 
cutting corners; however, in the case of cancer patients who are willing to 
take more risk, adaptive trials are acceptable.  
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The Use of Bayesian Statistics in New Drug Trials 
 A finding in the Brownback Bill (2005) criticized the FDA for 
relying on antiquated statistical methods that slowed drug development. 
Therefore, Bayesian statistics are now being used in many Phase I and 
Phase II trials at the National Cancer Institute. This statistical method 
assigns a probability to unknowns, using information from previous 
experiments. As in adaptive trials, information is continually being 
updated. Doctors using this approach are able to look at multiple 
treatment combinations and determine patient response by looking at 
the effect of the drug on particular cancer biomarkers (Berry, 2006).  
  
Targeted Cancer Therapies 
As a general rule, chemotherapy for any cancer has been based on 
a one-size-fits-all approach. However, there are now a wide range of 
available technologies, such as genomics and proteomics that are used in 
the development of new targeted drug treatments. Targeted therapies use 
drugs that block the growth and spread of cancer by interfering with 
specific molecules that are involved with the process by which normal 
cells become cancer (National Cancer Institute Targeted Cancer 
Therapies, 2007).  
Trials of a targeted therapy may be run as early as Phase II of drug 
testing. Subpart H of the Code of Federal Regulations [21 CFR 314.510] 
allows drugs to be approved on the basis of surrogate endpoints. In the 
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case of a cancer trial, the surrogate endpoint would usually be tumor 
shrinkage or lack of advancement in size of the tumor. New imaging 
technology has made such endpoints easier to determine. Thus, cancer 
patients with unmet needs now have access to drugs that have 
demonstrated effectiveness against a surrogate marker that is 
“reasonably likely” to predict clinical benefit, based on an endpoint other 
than survival or irreversible morbidity.  
 
Conclusion 
The FDA has admitted that the process of approving new drugs 
and transforming new technologies developed in clinical laboratories into 
safe and effective treatments available to all patients has been slow and 
difficult. Driven by the hope of a “breakthrough,” cancer patients are 
increasingly trying to gain access to experimental drugs before the drugs 
have received FDA approval. However, giving patients access to drugs 
that are in the early stages of testing is dangerous and undermines the 
integrity of the clinical trial system by slowing enrollment. Thus, 
providing access to unapproved drugs to a few patients may actually 
slow the access for all patients. 
Through the Critical Path Initiative, the FDA has identified specific 
problems and is taking steps to move the drug approval process and 
clinical trial system into the 21st century. Acknowledging that perfecting 
the system will take years, the FDA has made many drugs available to 
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terminal patients through compassionate use programs. However, the 
importance of the clinical trial system in developing and testing new 
drugs for safety and efficacy cannot be overstated. For most cancer 
patients who have failed all approved forms of therapy, the safest way to 
access investigational drugs is through an FDA-approved clinical trial.  
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